#Post ADS3

advertisement

Febuxostat 40 or 80 mg

 

 

āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ, febuxostate 40/80mg

Material: Each tableteat contains Febuxostat INN 40mg And 80 mg
Instructions: indicated in the treatment of hyperuricemia infections caused by Fetuxostat Arthritis. Where there is no sign of hyperuricemia, it is not indicated.

Dimensions and Usage Rules: Fabusostat 40mg Or 80 mg To use once a day. Patients with serum uric acid should be 6 mg after 2 weeks For those not named below / desiliter, Febubstaatat 80 mg Indicated There is no relation between food or antacids using fibrocystate. There is no need to amend the febuxostate levels for patients with kidney and liver problems.

Caution:
1. In some cases, the possibility of an increase in arthritic pain before the start of febuxostate. Then use pain medicines or colchicin for 6 months without using febuxostate.
2. Patients with heart and stroke should use the advice of the doctor.
3. Be sure to check if the liver is functioning properly.

Side effects: Liver problems, nausea, orthopedic pain and red spots in the skin.

Consequences: Phybucostat can not be used for patients using Ajathioprin, Marcapitopurin or Theophylline.

Reactions with other drugs: There is a possibility of poisoning using azethoprine, marcapepticin or theophthylene with feboxostat.

Use during pregnancy and breastfeeding: Category 'C' drug for pregnancy. There is not enough information available during pregnancy, however, Facebook can be given only when there is reasonable confirmation of good health as compared to fetal losses. The mothers should be careful about breastfeeding.

Use of children: Safety and efficiencies of febuxostate are still not established for child patients.
āĻ‰āĻĒাāĻĻাāĻ¨:āĻĒ্āĻ°āĻ¤িāĻŸি āĻŸ্āĻ¯াāĻŦāĻ˛েāĻŸে āĻ°āĻ¯়েāĻ›ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ āĻ†āĻ‡āĻāĻ¨āĻāĻ¨ ā§Ēā§Ļ āĻŽি.āĻ—্āĻ°া. āĻāĻŦং ā§Žā§Ļ āĻŽি.āĻ—্āĻ°া.

āĻ¨িāĻ°্āĻĻেāĻļāĻ¨া : āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ āĻŦাāĻ¤ āĻ°োāĻ—ে āĻĒāĻ°িāĻ˛āĻ•্āĻˇিāĻ¤ āĻšাāĻ‡āĻĒাāĻ°āĻ‡āĻ‰āĻ°িāĻ¸েāĻŽিāĻ¯়াāĻ° āĻšিāĻ•িā§ŽāĻ¸াāĻ¯় āĻ¨িāĻ°্āĻĻেāĻļিāĻ¤। āĻ¯েāĻ–াāĻ¨ে āĻšাāĻ‡āĻĒাāĻ°āĻ‡āĻ‰āĻ°িāĻ¸েāĻŽিāĻ¯়াāĻ° āĻ•োāĻ¨ āĻ˛āĻ•্āĻˇāĻŖ āĻ¨েāĻ‡ āĻ¸েāĻ–াāĻ¨ে āĻ‡āĻšা āĻ¨িāĻ°্āĻĻেāĻļিāĻ¤ āĻ¨āĻ¯়।

āĻŽাāĻ¤্āĻ°া āĻ“ āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻŦিāĻ§ি : āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ ā§Ēā§Ļ āĻŽি.āĻ—্āĻ°া. āĻ…āĻĨāĻŦা ā§Žā§Ļ āĻŽি.āĻ—্āĻ°া. āĻĻিāĻ¨ে āĻāĻ•āĻŦাāĻ° āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°āĻ¤ে āĻšāĻŦে। āĻ¯েāĻ¸āĻŦ āĻ°োāĻ—ীāĻĻেāĻ° āĻ¸িāĻ°াāĻŽে āĻ‡āĻ‰āĻ°িāĻ• āĻāĻ¸িāĻĄেāĻ° āĻŽাāĻ¤্āĻ°া ā§¨ āĻ¸āĻĒ্āĻ¤াāĻš āĻĒāĻ°ে ā§Ŧ āĻŽি.āĻ—্āĻ°া. / āĻĄেāĻ¸িāĻ˛িāĻŸাāĻ° āĻāĻ° āĻ¨ীāĻšে āĻ¨াāĻŽে āĻ¨া āĻ¤াāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ ā§Žā§Ļ āĻŽি.āĻ—্āĻ°া. āĻ¨িāĻ°্āĻĻেāĻļিāĻ¤। āĻ–াāĻĻ্āĻ¯ āĻŦা āĻāĻ¨্āĻŸাāĻ¸িāĻĄেāĻ° āĻ¸াāĻĨে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸ্āĻ¯াāĻŸ āĻ¸েāĻŦāĻ¨েāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻ•োāĻ¨ āĻ¸āĻŽ্āĻĒāĻ°্āĻ• āĻ¨াāĻ‡। āĻ¯ে āĻ¸āĻŦ āĻ°োāĻ—ীāĻ° āĻ•িāĻĄāĻ¨ী āĻ“ āĻ˛িāĻ­াāĻ°ে āĻ¸āĻŽāĻ¸্āĻ¯া āĻ†āĻ›ে āĻ¤াāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ-āĻāĻ° āĻŽাāĻ¤্āĻ°া āĻ¸ংāĻļোāĻ§āĻ¨েāĻ° āĻ•োāĻ¨ āĻĒ্āĻ°āĻ¯়োāĻœāĻ¨ āĻ¨াāĻ‡।

āĻ¸াāĻŦāĻ§াāĻ¨āĻ¤া :
ā§§। āĻ•িāĻ›ু āĻ•িāĻ›ু āĻ°োāĻ—ীāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻļুāĻ°ুāĻ° āĻĒ্āĻ°āĻĨāĻŽে āĻŦাāĻ¤েāĻ° āĻŦ্āĻ¯āĻĨা āĻŦেāĻĄ়ে āĻ¯াāĻ“āĻ¯়াāĻ° āĻ¸āĻŽ্āĻ­াāĻŦāĻ¨া āĻĨাāĻ•ে। āĻ¤āĻ–āĻ¨ āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻŦāĻ¨্āĻ§ āĻ¨া āĻ•āĻ°ে āĻāĻ° āĻ¸াāĻĨে āĻŦ্āĻ¯āĻĨাāĻ° āĻ“āĻˇুāĻ§ āĻŦা āĻ•োāĻ˛āĻšিāĻšিāĻ¨ ā§Ŧ āĻŽাāĻ¸ āĻĒāĻ°্āĻ¯āĻ¨্āĻ¤ āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°āĻ¤ে āĻšāĻŦে।
ā§¨। āĻšাāĻ°্āĻŸেāĻ° āĻāĻŦং āĻ¸্āĻŸ্āĻ°োāĻ•েāĻ° āĻ°োāĻ—ীāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĄাāĻ•্āĻ¤াāĻ°েāĻ° āĻĒāĻ°াāĻŽāĻ°্āĻļাāĻ¨ুāĻ¯াāĻ¯়ী āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°āĻ¤ে āĻšāĻŦে।
ā§Š। āĻ˛িāĻ­াāĻ° āĻ¸āĻ িāĻ•āĻ­াāĻŦে āĻ•াāĻœ āĻ•āĻ°āĻ›ে āĻ•িāĻ¨া āĻ¤া āĻ˛āĻ•্āĻˇ্āĻ¯ āĻ°াāĻ–āĻ¤ে āĻšāĻŦে।

āĻĒাāĻ°্āĻļ্āĻŦ āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া : āĻ˛িāĻ­াāĻ°ে āĻ¸āĻŽāĻ¸্āĻ¯া, āĻŦāĻŽি āĻŦāĻŽি āĻ­াāĻŦ, āĻ…āĻ¸্āĻĨিāĻ¸āĻ¨্āĻ§িāĻ¤ে āĻŦ্āĻ¯āĻĨা āĻ“ āĻšাāĻŽāĻĄ়াāĻ¤ে āĻ˛াāĻ˛ āĻĻাāĻ— āĻšāĻ“āĻ¯়া।

āĻĒ্āĻ°āĻ¤িāĻ¨িāĻ°্āĻĻেāĻļāĻ¨া : āĻ¯ে āĻ¸āĻ•āĻ˛ āĻ°োāĻ—ী āĻ…্āĻ¯াāĻœাāĻĨিāĻ“āĻĒ্āĻ°িāĻ¨, āĻŽাāĻ°āĻ•্āĻ¯াāĻĒāĻŸোāĻĒিāĻ‰āĻ°িāĻ¨ āĻŦা āĻĨিāĻ“āĻĢাāĻ‡āĻ˛িāĻ¨ āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°āĻ›ে āĻ¤াāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻŦ্āĻ¯āĻŦāĻšাāĻ° āĻ•āĻ°া āĻ¯াāĻŦে āĻ¨া।

āĻ…āĻ¨্āĻ¯ āĻ“āĻˇুāĻ§েāĻ° āĻ¸াāĻĨে āĻĒ্āĻ°āĻ¤িāĻ•্āĻ°িāĻ¯়া : āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻāĻ° āĻ¸াāĻĨে āĻāĻ¯াāĻĨিāĻ“āĻĒ্āĻ°িāĻ¨, āĻŽাāĻ°āĻ•্āĻ¯াāĻĒāĻŸোāĻĒিāĻ‰āĻ°িāĻ¨ āĻŦা āĻĨিāĻ“āĻĢাāĻ‡āĻ˛িāĻ¨েāĻ° āĻŦ্āĻ¯āĻŦāĻšাāĻ°ে āĻŦিāĻˇāĻ•্āĻ°িāĻ¯়াāĻ° āĻ¸āĻŽ্āĻ­াāĻŦāĻ¨া āĻĨাāĻ•ে।

āĻ—āĻ°্āĻ­াāĻŦāĻ¸্āĻĨাāĻ¯় āĻ“ āĻ¸্āĻ¤āĻ¨্āĻ¯āĻĻাāĻ¨āĻ•াāĻ˛ে āĻŦ্āĻ¯āĻŦāĻšাāĻ° : āĻ—āĻ°্āĻ­াāĻŦāĻ¸্āĻĨাāĻ° āĻœāĻ¨্āĻ¯ āĻ•্āĻ¯াāĻŸাāĻ—āĻ°ি ‘āĻ¸ি’ āĻ“āĻˇুāĻ§। āĻ—āĻ°্āĻ­াāĻŦāĻ¸্āĻĨাāĻ¯় āĻŦ্āĻ¯āĻŦāĻšাāĻ°েāĻ° āĻĒāĻ°্āĻ¯াāĻĒ্āĻ¤ āĻ¤āĻĨ্āĻ¯ āĻĒাāĻ“āĻ¯়া āĻ¯াāĻ¯়āĻ¨ি āĻ¤āĻŦে āĻ¯āĻ–āĻ¨ āĻ­্āĻ°ুāĻŖেāĻ° āĻ•্āĻˇāĻ¤িāĻ° āĻ¤ুāĻ˛āĻ¨াāĻ¯় āĻ¸ুāĻ¸্āĻĨāĻ¤াāĻ° āĻ…āĻ§িāĻ• āĻ¨িāĻļ্āĻšāĻ¯়āĻ¤া āĻ¯ুāĻ•্āĻ¤িāĻ¸āĻ™্āĻ—āĻ¤ āĻĒ্āĻ°āĻŽাāĻ¨িāĻ¤ āĻšāĻŦে āĻ¤āĻ–āĻ¨āĻ‡ āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻĻেāĻ¯়া āĻ¯েāĻ¤ে āĻĒাāĻ°ে। āĻ¸্āĻ¤āĻ¨্āĻ¯āĻĻাāĻ¨āĻ•াāĻ°ী āĻŽাāĻ¯়েāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻ¸াāĻŦāĻ§াāĻ¨āĻ¤া āĻ…āĻŦāĻ˛āĻŽ্āĻŦāĻ¨ āĻ•āĻ°āĻ¤ে āĻšāĻŦে।

āĻļিāĻļুāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻŦ্āĻ¯āĻŦāĻšাāĻ° : āĻļিāĻļু āĻ°োāĻ—ীāĻĻেāĻ° āĻ•্āĻˇেāĻ¤্āĻ°ে āĻĢেāĻŦুāĻ•্āĻ¸োāĻ¸্āĻŸাāĻŸ āĻāĻ° āĻ¨িāĻ°াāĻĒāĻ¤্āĻ¤া āĻ“ āĻ•াāĻ°্āĻ¯āĻ•াāĻ°িāĻ¤া āĻāĻ–āĻ¨āĻ“ āĻĒ্āĻ°āĻ¤িāĻˇ্āĻ িāĻ¤ āĻšāĻ¯়āĻ¨ি।


Post a Comment

0 Comments

advertisement

advertisement